Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 3/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23753406 | 0.96 | LIPG (0.47) | AAK1BACE1BACE2USP30PAX8 | |
| SCHEMBL12185974 | 0.87 | BACE1 (0.49) | AAK1BACE1BACE2USP30F11 | |
| SCHEMBL18204544 | 0.85 | BACE1 (0.45) | AAK1BACE1BACE2USP30F11 | |
| SCHEMBL1750582 | 0.84 | BRD4 (0.44) | AAK1BACE1BACE2USP30PAX8 | |
| SCHEMBL17419130 | 0.84 | CA1 (0.43) | AAK1F11CA1CA2CA9 | |
| SCHEMBL1019640 | 0.84 | BACE1 (0.45) | AAK1BACE1BACE2USP30F11 | |
| SCHEMBL2592445 | 0.83 | USP30 (0.57) | AAK1BACE1BACE2USP30F11 | |
| SCHEMBL30175895 | 0.83 | BACE1 (0.46) | AAK1BACE1BACE2USP30F11 | |
| SCHEMBL2595119 | 0.83 | AAK1 (0.45) | AAK1BACE1BACE2USP30F11 | |
| SCHEMBL13394297 | 0.82 | BRD4 (0.39) | AAK1BACE1BACE2USP30PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-24 | — | — | US | disclosed |
| US-11884721-B2 | Erythrocyte-binding therapeutics | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2024-01-30 | — | — | US | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220125945-A1 | COMPOSITIONS AND METHODS FOR INDUCING ANTIGEN-SPECIFIC TOLERANCE | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2022-04-28 | — | — | US | disclosed |
| US-11246943-B2 | Antigen-specific tolerance and compositions for induction of same | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2022-02-15 | — | — | US | disclosed |
| EP-3426653-B1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-08-12 | — | — | US | disclosed |
| US-20210238277-A1 | ERYTHROCYTE-BINDING THERAPEUTICS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20210079077-A1 | ERYTHROCYTE-BINDING THERAPEUTICS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008034860-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| EP-1844056-A2 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| US-20060167030-A1 | Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066957-A2 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167030-A1 | Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof | TEK, KDR, FLT1 | AAK1 1264/4885BACE1 1952/4885BACE2 997/4885 |
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | AAK1 651/4885BACE1 1797/4885BACE2 628/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | AAK1 651/4885BACE1 1797/4885BACE2 628/4885 |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | TOP1, TOP2A, TOP2B | AAK1 2502/4885BACE1 1714/4885BACE2 2365/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | AAK1 1134/4885BACE1 1819/4885BACE2 2627/4885 |
| US-20080220003-A1 | C5a Receptor Antagonists | C3AR1, C5AR2, C5AR1 | AAK1 3853/4885BACE1 4226/4885BACE2 4131/4885 |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | TOP1, TOP2A, TOP2B | AAK1 2502/4885BACE1 1714/4885BACE2 2365/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | AAK1 1674/4885BACE1 2173/4885BACE2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.